News Releases

Date Title and Summary
Toggle Summary National Institute of Health Research (NIHR) publication reinforces potential role of gammaCore in helping UK patients manage medically unexplained symptoms (MUS)
electroCore welcomes the recent NIHR technology alert on gammaCore, which profiles the CE-marked device’s role in helping patients in the UK manage long-term neurological conditions such as migraine and medically unexplained symptoms. The alert, which is designed to notify clinicians and those
Toggle Summary NICE provides positive guidance on electroCore’s gammaCore treatment for the prevention and acute treatment of migraine and cluster headache.
BASKING RIDGE, N.J: The UK’s National Institute of Health and Care Excellence (NICE) has published guidance that electroCore’s non-invasive vagus nerve stimulation treatment (gammaCore) for the prevention and acute treatment of migraine and cluster headache is safe and can now be used in the NHS. 
Toggle Summary University of Bonn study shows that non-invasive vagus nerve stimulation (nVNS) device reduces number of migraine attacks and their intensity
A study published in the Journal of Headache and Pain, carried out by Dr. Thomas Kinfe of the University of Bonn, found that twice daily stimulation of the vagus nerve with the hand-held gammaCore nVNS device reduced the number of headache days per month from 14.7 to 8.9 (p
Toggle Summary ElectroCore appoints Desitin to launch gammaCore for the treatment of primary headache across Germany
Basking Ridge, New Jersey: ElectroCore’s non-invasive vagus nerve stimulation device, gammaCore, will be launched across Germany by Desitin for the treatment of migraine and cluster headache. The agreement with Desitin who are specialists in the CNS area took effect on January 1st, 2016.  Desitin,